Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

Novo Nordisk slashes Wegovy prices by 50% for cash-paying patients amid Trump's pressure on drugmakers to reduce costs.

Drugmaker Novo Nordisk received accelerated approval for the drug’s use in people with moderate to advanced liver scarring, ...

GreensKeeper Asset Management, an investment management company, released its second-quarter 2025 investor letter. A copy of ...

The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis. About 14.9 million U.S.

Burke Wealth Management, an investment management company, released its “Focused Growth Strategy” second-quarter 2025 ...

The poor condition of Bhiwandi’s roads and chaotic traffic continues to make commuting dangerous, often resulting in ...

Sanjay Malhotra, Governor, Reserve Bank of India , said that India is at a critical juncture of navigating through a choppy ...

Some firms see investments in the outsourcing of drugmaker operations as a hedge against tariff tumult.